Although OSM has been proposed as a novel therapeutic target for metabolic syndrome, further research is warranted to provide insights into its role in inflammation, insulin resistance, and lipid metabolism in the context of obesity-related metabolic syndrome. Here, OSM is linked to obesity due to melanocortin 4 receptor deficiency.